Takeda Pharmaceutical Company Limited (TAK)
After hours: 07:40PM EDT
| Previous close | 14.02 |
| Open | 14.03 |
| Bid | 13.95 x 3000 |
| Ask | 14.11 x 2900 |
| Day's range | 13.97 - 14.10 |
| 52-week range | 13.91 - 19.97 |
| Volume | 1,492,068 |
| Avg. volume | 2,182,329 |
| Market cap | 44.251B |
| Beta (5Y monthly) | 1.10 |
| PE ratio (TTM) | 11.76 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.84 (5.97%) |
| Ex-dividend date | 30 Mar 2021 |
| 1y target est | N/A |
- Zacks
Seagen's (SGEN) Cancer Portfolio Strong, Stiff Rivalry a Worry
Seagen (SGEN) focuses on improving sales of its marketed drugs that are approved for different types of cancer indications. Stiff competition in the target market remains a woe.
- Motley Fool
Why Takeda Pharmaceutical Stock Is Down More Than 10% Today
The prescription drugmaker is halting a trial before a scheduled stopping point, suggesting it's too dangerous to expect an approval.
- Bloomberg
Japan Moderna Supplier Takeda Plans Its Second-Biggest Yen Bond
(Bloomberg) -- Takeda Pharmaceutical Co., a drugmaker that distributes Moderna Inc.’s vaccine in Japan, is planning what would be its second-biggest yen bond sale ever next week.The Tokyo-based company is scheduled to price a 200 billion yen ($1.8 billion) 10-year note on Oct. 8, and intends to use the funds to refinance its existing debt, according to underwriter SMBC Nikko Securities Inc. That would be its largest Japanese-currency sale after a jumbo 500 billion yen offering in 2019 to help pa
